Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

Anti-CD19 chimeric antigen receptor (CAR)-expressing T cells are an effective treatment for B-cell lymphoma, but often cause neurologic toxicity. We treated 20 patients with B-cell lymphoma on a phase I, first-in-human clinical trial of T cells expressing the new anti-CD19 CAR Hu19-CD828Z ( NCT02659...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature medicine 2020-02, Vol.26 (2), p.270-280
Hauptverfasser:	Brudno, Jennifer N., Lam, Norris, Vanasse, Danielle, Shen, Yueh-wei, Rose, Jeremy J., Rossi, John, Xue, Allen, Bot, Adrian, Scholler, Nathalie, Mikkilineni, Lekha, Roschewski, Mark, Dean, Robert, Cachau, Raul, Youkharibache, Philippe, Patel, Rashmika, Hansen, Brenna, Stroncek, David F., Rosenberg, Steven A., Gress, Ronald E., Kochenderfer, James N.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/250 631/250/251 692/308 692/308/2779/109/1940 692/308/575 692/699/67/1059/2325 692/699/67/1990/291 Adolescent Adult Aged Antigens Antigens, CD19 - immunology B cells B-cell lymphoma Binding Binding proteins Biomedical and Life Sciences Biomedicine Blood Blood levels Cancer Research Care and treatment CD19 antigen Cell therapy Chimeric antigen receptors Cytokines Cytokines - metabolism Development and progression Domains Feasibility Studies Female Health aspects Humans Immunogenicity Immunotherapy, Adoptive Infectious Diseases K562 Cells Levels Lymphocytes Lymphocytes B Lymphocytes T Lymphoma Lymphoma, B-Cell - immunology Lymphoma, B-Cell - therapy Lymphomas Male Metabolic Diseases Middle Aged Molecular Medicine Neurosciences Patients Phenotype Protein Domains Receptors, Chimeric Antigen - immunology Remission Remission Induction Safety Toxicity Transmembrane domains Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!